Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are considering adipose-derived stem cell therapy in Japan, one of the first practical questions is what the process actually looks like. Because the treatment uses your own cultured cells, it is not a single visit. It is a sequence of steps spread over several weeks, with an outpatient visit at the beginning and another at the end. This article walks through that sequence at Grand Green Osaka Umekita Clinic so you can prepare informed questions before you travel or book.
In short, the treatment involves a consultation, a small fat collection under local anesthesia, cell culture at a specialized facility, and an intravenous infusion of your own cultured mesenchymal stem cells. Exact timing, eligibility, and expected effects differ from person to person and must be confirmed with a physician.
Step 1: The consultation comes before anything else
Treatment does not begin with a procedure. It begins with a conversation with a doctor. At the consultation, the physician reviews your medical history, your current symptoms, and what you hope to achieve. This is also the time to discuss whether adipose-derived stem cell therapy is an appropriate option at all, or whether other approaches, including standard medical care, may suit you better.
Because this is a self-pay (non-insured) treatment, you should also confirm the fees, the number of infusions, the expected schedule, and the possible risks and side effects at this visit. Regenerative medicine is still an evolving field, and research on mesenchymal stem cells has not established the same level of evidence for every condition. A careful clinic will explain the limits of current knowledge rather than promise a particular outcome.
Clinics in Osaka that welcome international patients often provide an information page in several languages. Grand Green Osaka Umekita Clinic offers a page for foreign patients, which can help you gather your questions before the first appointment.
Step 2: Collecting a small amount of fat
If you and your doctor decide to proceed, the next step is collecting fat tissue. According to the clinic’s treatment information, the amount needed is very small, roughly the size of a few grains of rice, and the collection is performed under local anesthesia through a small incision. This is done on an outpatient basis, so hospitalization is not required.
Fat is used as a source of mesenchymal stem cells because adipose tissue is generally considered to contain a substantial number of them, and collecting it places a smaller burden on the body than bone marrow collection. Even so, any procedure that involves an incision carries some possibility of bleeding, bruising, infection, or discomfort at the collection site. Ask your doctor how these are managed and what to watch for afterward.
- Tell your doctor about any medicines you take, especially blood thinners.
- Mention allergies, including to local anesthetics.
- Ask what aftercare instructions to expect and whom to contact if you have concerns.
Step 3: Culture and quality checks take place away from the clinic
After collection, the fat tissue is sent to a specialized cell processing facility. There, the mesenchymal stem cells are isolated and cultured so that their number can be increased to the amount needed for infusion. This stage takes time, which is why the treatment cannot be completed in a single day.
In Japan, facilities that process cells for regenerative medicine operate under a regulatory framework, and the clinic provides treatment under a plan submitted under the Act on the Safety of Regenerative Medicine. Quality and safety checks are a normal part of this system. If you want to understand them in more detail, ask the clinic what checks are performed and how the schedule is communicated to you.
For international patients, this waiting period matters for planning. Ask in advance how long the culture period is expected to be and what happens if the schedule changes, so that you can arrange travel with some flexibility.
Step 4: The intravenous infusion
Once the cultured cells are ready, you return to the clinic for the infusion. The cells are administered by intravenous drip, again on an outpatient basis. Infused mesenchymal stem cells have been reported to move through the bloodstream and gather at sites of inflammation or damage, a phenomenon often called homing. This is a reported finding from research, and it should not be read as a promise of a particular result in any individual.
Because the cells come from your own body, the risk of rejection or allergic reaction is generally considered lower than with donor cells, but this does not mean that no adverse reaction can occur. Your doctor can explain which reactions are possible during or after an infusion and how they would be handled.
Questions worth preparing before you visit Osaka
A visit to a clinic in Umeda, Osaka, is easier when you arrive with specific questions. The following list may help you structure the first consultation.
- Is adipose-derived stem cell therapy suitable for my condition, and what are the alternatives?
- What are the total fees, and what is included?
- How many visits are needed, and over what period?
- What risks and side effects should I know about, both from the fat collection and from the infusion?
- What does the clinic do if I experience a problem after I return home?
- Can my records be provided in a language I can read?
The answers will depend on your health and on the physician’s judgment. Treat this article as general information, not as medical advice, and make any decision together with a doctor who has examined you.
Summary
Adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic follows a clear sequence: consultation, outpatient fat collection under local anesthesia, cell culture at a specialized facility, and intravenous infusion. It is a self-pay treatment provided under Japan’s regenerative medicine regulations, and its costs, risks, side effects, and suitability must be confirmed at a medical consultation. If you are considering treatment in Osaka, the clinic’s multilingual information page and a direct consultation are sensible places to begin.
- 1ConsultationDoctor reviews your history
- 2Fat collectionLocal anesthesia, outpatient
- 3Cell cultureAt a specialized facility
- 4IV infusionOutpatient visit
This figure is a conceptual diagram summarizing the article
References
- PubMed: Glycocalyx-edited mesenchymal stem/stromal cell therapy in advanced osteoporosis. (2026)
- PubMed: Can Autologous Adipose-Derived Mesenchymal Stem Cell Transplantation Improve Sexual Function in People with Sexual Functional Deficiency? (2021)
- PubMed: Adipose-derived mesenchymal stem cells for the treatment of Amyotrophic Lateral Sclerosis. A phase I/II safety and efficacy clinical trial. (2025)
- PubMed: Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series. (2024)
- PubMed: Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)
- PMC: Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial. (2026)
- PMC: Functional recovery of a 41-year-old quadriplegic spinal cord injury patient following multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells: a case report. (2023)
- PMC: A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy. (2025)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.